{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:02:37Z","timestamp":1747184557080,"version":"3.40.5"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Because of lacking of head\u2010to\u2010head comparison among recently effective novel agents\u2019 combination regimens for newly diagnosed patients with mantle\u2010cell lymphoma (MCL) who are ineligible for intensive therapy like autologous stem\u2010cell transplantation, the optimal option for these patients still remains undefined. We searched relevant published reports. Three randomized controlled trials with 1459 subjects were identified. In the network meta\u2010analysis, ibrutinib plus bendamustine and rituximab (Ibru\u2009+\u2009BR) significantly improved progression\u2010free survival (PFS) when compared to bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR\u2010CAP; hazard ratio [HR]: 0.55, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.03) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R\u2010CHOP; HR: 0.35, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001) for newly diagnosed patients with MCL ineligible for intensive therapy. Among these first\u2010line treatment regimens (Ibru\u2009+\u2009BR, VR\u2010CAP, R\u2010CHOP, and BR), Ibru\u2009+\u2009BR had the highest probability of 94.9% to be the best intervention in PFS analysis. No significant difference was found in adverse events analysis. Our data indicated that Ibru\u2009+\u2009BR seemed to prolong the PFS when compared to VR\u2010CAP and R\u2010CHOP for newly diagnosed patients with MCL ineligible for intensive therapy. Considering our limits, prospective clinical trials directly comparing these regimens are warranted.<\/jats:p>","DOI":"10.1111\/ejh.13953","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T06:53:40Z","timestamp":1678863220000},"page":"602-607","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle\u2010cell lymphoma ineligible for intensive therapy: A network meta\u2010analysis"],"prefix":"10.1111","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-7875","authenticated-orcid":false,"given":"Zhixin","family":"Sheng","sequence":"first","affiliation":[{"name":"Department of Hematology Weifang People's Hospital  Weifang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lida","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of E.N.T Weifang People's Hospital  Weifang Shandong China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.568"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23615"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0488"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1605511"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103212"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15283"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"e_1_2_11_13_1","unstructured":"National Comprehensive Cancer Net\u2010work (NCCN).Clinical practice guidelines in oncology: B\u2010cell lymphomas Version 5.2021.https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu264"},{"volume-title":"NCCN Clinical Practice Guidelines in Oncology: Non\u2010Hodgkin's Lymphomas, Version 5","year":"2014","author":"National Comprehensive Cancer Network (NCCN)","key":"e_1_2_11_19_1"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7504"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.75_2631"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7503"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01294"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13953","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13953","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:41:31Z","timestamp":1692632491000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/ejh.13953"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13953","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"2022-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}